Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATO and ATRA in NPM1-mutated AML
NCT03031249Phase 2Enrolling by invitation
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2017
- Primary completion
- May 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of arsenic trioxide and tretinoin in acute myeloid leukemia (AML) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Relapse-Free Survival at 5 years. Started Feb 2017; status: enrolling by invitation.
02
Drugs
arsenic trioxidetretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03031249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031249.